• Private Equity, Sovereign Wealth Funds and Strategics

    • One Equity Partners on its sale of PeroxyChem to Evonik Industries AG (FRA:EVK), a German-based publicly traded global specialty chemicals company; its acquisition of Anvil International, a leading North American manufacturer of pipe fitting and system components from Mueller Water Products (NYSE:MWA) and subsequent sale of Anvil International to Smith-Cooper International; its acquisition of a majority interest in The W.W. Williams Company; and in a number of buyout and exit transactions, as well as advising a number of portfolio companies on add-on acquisitions.
    • MiddleGround Capital in its acquisition of Plasman Holdings, a single-source solutions provider to automotive original equipment manufacturers for exterior products and systems; Arrow Tru-Line, an independent manufacturer and supplier of overhead garage door hardware components, selling into residential and commercial markets; and Dura Automotive Systems, a global automotive supplier specializing in the design, engineering, and manufacturing of solutions that drive the evolution of mobility.
    • GIC in connection with the combination of Alight Solutions with Foley Trasimene Acquisition Corp., which implies a pro-forma enterprise value for Alight of approximately $7.3 billion.
    • GIC in the sale of Refinitiv by a consortium (consisting of Blackstone, an affiliate of GIC, Canada Pension Plan Investment Board and Thomson Reuters) to London Stock Exchange Group plc. 
    • SciPlay Corporation (NASDAQ:SCPL), a leading developer and publisher of digital games on mobile and web platforms, in its acquisition of Alictus, a global developer and publisher of casual mobile games.
    • Berwind Group on the sale of Specialty Coating Systems to KISCO Ltd. of Japan.
    • Macquarie Corporate and Asset Finance on its sale of a BNSF Logistics Facility to funds managed by CRIC2 Funds, LLC.
    • CDI Corp. on its acquisition of EdgeRock Technologies, LLC.

    Business Development Companies and Financial Services

    • Numerous business development companies sponsored by FS Investments in connection with their multi-billion dollar continuous equity offerings, debt offerings and general corporate and securities matters.
    • Stifel Financial Corp. (NYSE:SF) on its strategic collaboration with LFE Capital, a growth equity firm dedicated to providing capital to women-owned and managed health and wellness businesses; its launch of Twelve Degrees, a strategic collaboration with RCP Advisors that is focused on investing in and providing capital solutions to leading emerging and first-time alternative investment fund managers; its acquisition of the public finance operations of George K. Baum & Company; its acquisition of Eaton Partners, LLC, one of the world’s largest capital placement agents and fund advisory firms; and in its investment in CM Investment Partners and CM Finance; and in connection with Stifel Aviation Finance, a series of aircraft specialty finance vehicles.
    • FS Investment Corporation (NYSE:FSK) in its merger with Corporate Capital Trust, Inc. (formerly NYSE:CCT), two publicly-listed, business development companies advised by FS/KKR Advisor, to create the second largest publicly-traded BDC by assets under management.
    • FS Investment Corporation II, FS Investment Corporation III, FS Investment Corporation IV and Corporate Capital Trust II in their merger to create the second largest BDC by assets under management.
    • PennantPark Investment Corporation (NYSE:PNNT) and PennantPark Floating Rate Capital Ltd. (NYSE:PFLT) in connection with their joint venture and capital markets activities and general corporate and securities matters.
    • FS Investments on its acquisition of Chiron Investment Management.
    • AIG (NYSE:AIG) in its acquisition of all the outstanding equity interests of Covenant Credit Partners, LP, an alternative credit manager with a focus on CLOs.

    Life Sciences

    • Edge Therapeutics (formerly NASDAQ:EDGE), a U.S.-based biotechnology company, in connection with its merger with PDS Biotechnology Corporation, a privately-held, clinical-stage cancer immunotherapy company.
    • Aviragen Therapeutics, Inc. (formerly NASDAQ:AVIR), a biopharmaceutical company that had been focused on the discovery and development of products to prevent and treat infectious diseases, in its merger with Vaxart, Inc. (NASDAQ:VXRT).
    • Celgene Corporation on its collaboration with Sutro BioPharma.
    • Philadelphia Bar Association
    • Delaware Court of Chancery, Honorable John W. Noble